Tianafac (also known as L8109) is a thienylacetic acid derivative patented by Labaz group as antipyretics and anti-inflammatory agent useful for the treatment of arthritis. In preclinical models, Tianafac inhibits prostaglandin formation by seminal vesicle microsomes and exerts antipyretic, analgetic, and moderate gastric ulcerogenic activity and had a wide safety margin between toxic and pharmacologically active doses.

Pipoxizine is the antihistamine agent and antiserotonin agent. It was used as antiarrhythmic and bronchodilator.

Mopidralazine is slower in onset and longer lasting than hydralazine and is devoid of adrenergic system stimulation. Its antihypertensive action is mediated by arteriolar dilatation. In the rat, Mopidralazine is rapidly metabolized, mainly by pyrrole-ring opening and subsequent formation of a mesoionic 3-(1-pyridazinyl)pyridazine In dogs, oxidative cleavage of the morpholine ring has been found to be the primary metabolic attack. In a small clinical trial, Mopidralazine resulted in significant reductions in blood pressure, both supine and standing, which was maximal 4-8 h after dosing, with no additional orthostatic component.

Piprocurarium is a curarimimetic. It is antagonized by neostigmine. Piprocurarium is strongly vagolytic, producing tachicardia. Its duration of action is shorter than that of d-tubocurare and longer than that of succinylcholine. Piprocurarium is not hypotensive, is only slightly histaminogenic, is nonirritating to the veins, and can be mixed with all the anesthetic drugs. Piprocurarium has been offered for clinical trial as a brief-acting, nondepolarizing neuromuscular blocking drug. The drug appears to be anything but short acting. A persistent tachycardia and elevation in systolic and diastolic pressure invariably follows its intravenous injection. Alarming electrocardiographic changes occur, characterized by AV dissociation, depression of the ST segment, supraventricular tachycardia and, at times, inversion of the T waves. In view of these circulatory effects, it is doubtful that the drug will be useful clinically.

Amiperone is a neuroleptic drug. It prolonged the latency (T) and reduced the frequency (F) of the noise escape response rate in rats. It also inhibited lever-press response and reduced the shock-avoidance rate at very low dose levels in rats.

Information in the literature related to the biological and/or pharmacological properties of molracetam is absent.

Aditoprim is a long-acting, selective, reversible inhibitor of dihydrofolate reductase with application as a broad-spectrum antibacterial agent in animals. Aditoprim is low toxic and not mutagenic.Many gram-positive and gram-negative bacteria are highly susceptible or susceptible to Aditoprim, especially Salmonella and Streptococcus, while H. parasuis and Klebsiella were moderately susceptible to Aditoprim. Phase II clinical study of Aditoprim on therapeutic effect on swine streptococcosis has demonstrated that Aditoprim is as active as compound sulfadiazine, which provides reasonable theoretical foundation for the clinical application of Aditoprim.

Deditonium is an antibacterial compound developed by the French company Centre de Recherches des Laboratoires Diamant. Deditonium is a quaternary ammonium derivative and has a bacteriostatic action at concentrations ranging from 1x10-6 to 5x10-4 M. Gram-positive cocci were found to be the most sensitive as well as many enterobacteria.

Etipirium is an antihaemorrhagic and spasmolytic drug.

Pituxate is the antitussive and bronchospasmolytic agent.